Download pdf
Enhancing Immunogenicity on COVID-19 mRNA Vaccine with Lipid Nanoparticles and Innovation of Nanotechnology
- 1 College of Arts and Sciences, University of Washington, Seattle, 98105, United States
* Author to whom correspondence should be addressed.
Abstract
The review highlights recent advancements in mRNA vaccine technology, focusing on the key mechanism of increasing vaccine immunogenicity through lipid nanoparticle (LNP) and its successful application to a COVID-19 vaccine. Optimized mRNA design, coupled with chemical modifications, such as pseudouridine substitution, have enhanced mRNA stability, translational efficiency, and minimized immune-related adverse reactions. Moreover, LNP optimization, through adjusting the ratio of ionized lipid, phospholipid, and cholesterol and regulating the nanoparticle size and surface charge, has proven critical for efficient vaccine delivery and robust immune responses. The review also discusses different administration routes and dosing regimens, emphasizing intramuscular injection as the most effective for systemic immune activation. The successful development of COVID-19 vaccines, as represented by Pfizer and Modena vaccines, supports the importance of those technologies and provides a new paradigm for future vaccine development. Continued optimization of LNP technology and the exploration of novel delivery systems are essential for extending the scope of mRNA vaccines to combat a broader range of diseases, ultimately providing innovative solutions to global health challenges.
Keywords
mRNA vaccine, lipid nanoparticle, immunogenicity, COVID-19
[1]. Park JW, Lagniton PNP, Liu Y, Xu RH. mRNA vaccines for COVID-19: what, why and how. International Journal of Biological Sciences [Internet]. 2021 Apr 10;17(6):1446–60. Available from: https://www.ijbs.com/v17p1446.pdf
[2]. Li B, Jiang AY, Raji I, Atyeo C, Raimondo TM, Gordon AGR, et al. Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA. Nature Biomedical Engineering [Internet]. 2023 Sep 7;1–18. Available from: https://www.nature.com/articles/s41551-023-01082-6
[3]. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nature Reviews Drug Discovery [Internet]. 2018 Jan 12;17(4):261–79. Available from: https://www.nature.com/articles/nrd.2017.243
[4]. Amruta Bhate, Parker DJ, Bebee TW, Ahn J, Arif W, Rashan EH, et al. ESRP2 controls an adult splicing programme in hepatocytes to support postnatal liver maturation. Nature Communications. 2015 Nov 4;6(1). Available from: https://doi.org/10.1038/ncomms9768
[5]. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials [Internet]. 2021 Aug 10;6(6):1078–94. Available from: https://www.nature.com/articles/s41578-021-00358-0
[6]. Guerrini G, Magrì D, Gioria S, Medaglini D, Calzolai L. Characterization of nanoparticles-based vaccines for COVID-19. Nature Nanotechnology [Internet]. 2022 Jun 1;17(6):570–6. Available from: https://www.nature.com/articles/s41565-022-01129-w#citeas
[7]. Cullis PR, Felgner PL. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nature Reviews Drug Discovery [Internet]. 2024 Jul 4; Available from: https://www.nature.com/articles/s41573-024-00977-6
[8]. Pardi N, Krammer F. mRNA vaccines for infectious diseases — advances, challenges and opportunities. Nature Reviews Drug Discovery. 2024 Oct 4;23(11). Available from: https://doi.org/10.1038/s41573-024-01042-y
[9]. Lee Y, Jeong M, Park J, Jung H, Lee H. Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics. Experimental & Molecular Medicine [Internet]. 2023 Oct 2 [cited 2023 Oct 25];1–12. Available from: https://www.nature.com/articles/s12276-023-01086-x
[10]. Bitounis D, Jacquinet E, Rogers MA, Amiji MM. Strategies to reduce the risks of mRNA drug and vaccine toxicity. Nature Reviews Drug Discovery [Internet]. 2024 Jan 23;1–20. Available from: https://www.nature.com/articles/s41573-023-00859-3
[11]. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine [Internet]. 2020 Dec 10;383(27):2603–15. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2034577
[12]. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. The New England Journal of Medicine. 2021 Feb 24;384(15). Available from: https://doi.org/10.1056/NEJMoa2101765
[13]. Baden LR, El Sahly HM, Essink B. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine. 2020 Dec 30;384(5):403–16. Available from: https://doi.org/10.1056/nejmoa2035389
[14]. Kim J, Eygeris Y, Gupta M, Sahay G. Self-assembled mRNA vaccines. Advanced Drug Delivery Reviews [Internet]. 2021 Mar 1;170:83–112. Available from: https://www.sciencedirect.com/science/article/pii/S0169409X20302933
[15]. Santos P, Almeida F. Exosome-Based Vaccines: History, Current State, and Clinical Trials. Frontiers in Immunology. 2021 Jul 14;12. Available from: https://doi.org/10.3389/fimmu.2021.711565
[16]. Shi Y, Shi M, Wang Y, You J. Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications. Signal Transduction and Targeted Therapy [Internet]. 2024 Nov 14 [cited 2024 Nov 16];9(1). Available from: https://www.nature.com/articles/s41392-024-02002-z
[17]. Huang Y, Guo X, Wu Y, Chen X, Feng L, Xie N, et al. Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment. Signal Transduction and Targeted Therapy [Internet]. 2024 Feb 21 [cited 2024 Mar 19];9(1):1–50. Available from: https://www.nature.com/articles/s41392-024-01745-z
[18]. Alesci A, Gitto M, Kotańska M, Lo Cascio P, Miller A, Nicosia N, et al. Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines. Human Immunology. 2022 Aug; Available from: https://doi.org/10.1016/j.humimm.2022.08.004
Cite this article
Wang,X. (2025). Enhancing Immunogenicity on COVID-19 mRNA Vaccine with Lipid Nanoparticles and Innovation of Nanotechnology. Theoretical and Natural Science,98,1-7.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 3rd International Conference on Modern Medicine and Global Health
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).